EA201491291A1 - АГОНИСТЫ mGlu 2/3 - Google Patents

АГОНИСТЫ mGlu 2/3

Info

Publication number
EA201491291A1
EA201491291A1 EA201491291A EA201491291A EA201491291A1 EA 201491291 A1 EA201491291 A1 EA 201491291A1 EA 201491291 A EA201491291 A EA 201491291A EA 201491291 A EA201491291 A EA 201491291A EA 201491291 A1 EA201491291 A1 EA 201491291A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agonists
mglu
neurological
treatment
present
Prior art date
Application number
EA201491291A
Other languages
English (en)
Other versions
EA023678B1 (ru
Inventor
Стивен Ричард Бейкер
Кристофер Дэвид Бидл
Барри Питер Кларк
Джеймс Аллен Монн
Лурдес Прието
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201491291A1 publication Critical patent/EA201491291A1/ru
Publication of EA023678B1 publication Critical patent/EA023678B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/26—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms containing rings other than aromatic rings
    • C07C55/30—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms containing rings other than aromatic rings containing condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предложены новые агонисты mGlu2/3, подходящие для применения для лечения неврологических или психических расстройств.
EA201491291A 2012-02-01 2013-01-29 Агонисты mglu 2/3 EA023678B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382038 2012-02-01
US201261619139P 2012-04-02 2012-04-02
PCT/US2013/023529 WO2013116174A1 (en) 2012-02-01 2013-01-29 Mglu 2/3 agonists

Publications (2)

Publication Number Publication Date
EA201491291A1 true EA201491291A1 (ru) 2014-10-30
EA023678B1 EA023678B1 (ru) 2016-06-30

Family

ID=48870759

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491291A EA023678B1 (ru) 2012-02-01 2013-01-29 Агонисты mglu 2/3

Country Status (35)

Country Link
US (1) US8575214B2 (ru)
EP (1) EP2809647B1 (ru)
JP (1) JP5755821B2 (ru)
KR (1) KR101518365B1 (ru)
CN (1) CN104093703B (ru)
AP (1) AP2014007821A0 (ru)
AR (1) AR089718A1 (ru)
AU (1) AU2013215396B2 (ru)
BR (1) BR112014018760A8 (ru)
CA (1) CA2863085C (ru)
CL (1) CL2014001928A1 (ru)
CO (1) CO7020921A2 (ru)
CR (1) CR20140344A (ru)
DK (1) DK2809647T3 (ru)
DO (1) DOP2014000179A (ru)
EA (1) EA023678B1 (ru)
ES (1) ES2592166T3 (ru)
GT (1) GT201400168A (ru)
HK (1) HK1199014A1 (ru)
HR (1) HRP20160867T1 (ru)
HU (1) HUE028863T2 (ru)
IL (1) IL233732A0 (ru)
LT (1) LT2809647T (ru)
MA (1) MA35884B1 (ru)
MX (1) MX355779B (ru)
NZ (1) NZ626456A (ru)
PE (1) PE20141680A1 (ru)
PH (1) PH12014501725A1 (ru)
PL (1) PL2809647T3 (ru)
PT (1) PT2809647T (ru)
RS (1) RS54976B1 (ru)
SG (1) SG11201404138VA (ru)
SI (1) SI2809647T1 (ru)
TW (1) TW201343610A (ru)
WO (1) WO2013116174A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101481164B1 (ko) * 2008-01-30 2015-01-09 주식회사 미래셀바이오 체세포 유래 다능성 줄기세포의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
NZ323205A (en) 1995-11-16 1999-06-29 Lilly Co Eli Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
ATE269293T1 (de) * 1998-08-31 2004-07-15 Taisho Pharmaceutical Co Ltd 6-fluoro(3.1.0)hexan-derivate
GB2355982A (en) * 1999-11-03 2001-05-09 Lilly Co Eli Heterocyclic amino acids
US6770676B2 (en) * 2000-06-28 2004-08-03 Taisho Pharmaceutical Co., Ltd. Dicarboxylic acid derivatives
NZ526050A (en) 2001-01-11 2005-03-24 Lilly Co Eli Prodrugs of excitatory amino acids
WO2002055485A1 (en) 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
NZ536459A (en) * 2002-06-11 2008-03-28 Lilly Co Eli Prodrugs of excitatory amino acids
KR101071507B1 (ko) 2003-06-26 2011-10-10 다이쇼 세이야꾸 가부시끼가이샤 2-아미노바이시클로〔3.1.0〕헥산-2,6-디카르복실산 에스테르 유도체
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids

Also Published As

Publication number Publication date
TW201343610A (zh) 2013-11-01
JP5755821B2 (ja) 2015-07-29
WO2013116174A1 (en) 2013-08-08
DOP2014000179A (es) 2014-10-15
PT2809647T (pt) 2016-08-29
AU2013215396A1 (en) 2014-07-17
CR20140344A (es) 2014-08-25
IL233732A0 (en) 2014-09-30
MA35884B1 (fr) 2014-12-01
US20130197079A1 (en) 2013-08-01
HK1199014A1 (en) 2015-06-19
ES2592166T3 (es) 2016-11-28
SG11201404138VA (en) 2014-08-28
AR089718A1 (es) 2014-09-10
DK2809647T3 (en) 2016-10-03
EP2809647B1 (en) 2016-07-06
PH12014501725A1 (en) 2014-11-24
US8575214B2 (en) 2013-11-05
AP2014007821A0 (en) 2014-07-31
BR112014018760A2 (ru) 2017-06-20
KR20140107658A (ko) 2014-09-04
HUE028863T2 (en) 2017-01-30
AU2013215396B2 (en) 2015-03-12
MX2014008598A (es) 2014-08-22
GT201400168A (es) 2015-08-27
CN104093703A (zh) 2014-10-08
SI2809647T1 (sl) 2016-08-31
CN104093703B (zh) 2016-01-20
JP2015512870A (ja) 2015-04-30
NZ626456A (en) 2016-02-26
LT2809647T (lt) 2016-10-10
RS54976B1 (sr) 2016-11-30
BR112014018760A8 (pt) 2017-07-11
KR101518365B1 (ko) 2015-05-08
CO7020921A2 (es) 2014-08-11
PE20141680A1 (es) 2014-11-08
CA2863085A1 (en) 2013-08-08
HRP20160867T1 (hr) 2016-10-07
EP2809647A1 (en) 2014-12-10
MX355779B (es) 2018-04-30
PL2809647T3 (pl) 2017-07-31
CL2014001928A1 (es) 2014-11-07
AU2013215396A8 (en) 2014-08-07
EA023678B1 (ru) 2016-06-30
CA2863085C (en) 2015-11-17

Similar Documents

Publication Publication Date Title
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
PH12015500525A1 (en) Formulations of enzalutamide
PH12015502788A1 (en) Antibody formulations and methods
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
UY33910A (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC
MX360710B (es) Antagonistas de il17c para el tratamiento de trastornos inflamatorios.
IN2014CN04014A (ru)
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
IN2015DN01524A (ru)
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
EA201691773A1 (ru) Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
EA201491291A1 (ru) АГОНИСТЫ mGlu 2/3
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
UY34667A (es) ?método y dispositivo para el tratamiento de trastornos del colesterol en la sangre?.
NZ723269A (en) Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
TN2014000303A1 (en) Mglu 2/3 agonists
ECSP14012098A (es) Agonistas de mglu 2/3

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM